Guardant Health, Inc. Forecast, price target & analysts
Why the stock moved Beta
Guardant Health, Inc. Target price 2026 - Analyst rating & recommendation
Guardant Health, Inc. Classifications & Recommendation
Guardant Health, Inc. Price Target
| Target Price | $204.00 |
| Price | $187.22 |
| Potential |
8.96%
register free of charge
|
| Number of Estimates | 30 |
|
30 Analysts have issued a price target Guardant Health, Inc. 2027 .
The average Guardant Health, Inc. target price is $204.00.
This is
8.96%
register free of charge
$236.25
26.19%
register free of charge
$93.33
50.15%
register free of charge
|
|
| A rating was issued by 35 analysts: 32 Analysts recommend Guardant Health, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2027 of
8.96%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 0.98 | 1.40 |
| 32.88% | 42.36% | |
| EBITDA Margin | -40.48% | -13.47% |
| 25.44% | 66.72% | |
| Net Margin | -42.39% | -15.13% |
| 28.21% | 64.31% |
32 Analysts have issued a sales forecast Guardant Health, Inc. 2026 . The average Guardant Health, Inc. sales estimate is
This results in the following potential growth metrics:
28 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2026. The average Guardant Health, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
32 Guardant Health, Inc. Analysts have issued a net profit forecast 2026. The average Guardant Health, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.32 | -1.58 |
| 6.74% | 52.41% | |
| P/E | negative | |
| EV/Sales | 17.39 |
32 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Guardant Health, Inc....
Current Guardant Health, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Oct 01 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Rothschild & Co |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Sep 02 2026 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Oct 01 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Rothschild & Co:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 02 2026 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 04 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
